EAPC Premium Access

Preventing cardiovascular disease in patients with T2DM: how to apply novel outcome data with GLP-1 ra to clinical practice.

Event: EuroPrevent 2018
Topic: Diabetes and the Heart
Session type: Satellite Symposium
Sponsored by PACE-CME: Physicians' Academy for Cardiovascular Education, supported with an educational grant by Novo Nordisk.
Date: 19 April 2018
Time: 12:45 - 13:45

Congress Session

5 presentations in this session

Introduction - Preventing cardiovascular disease in patients with T2DM: how to apply novel outcome data with GLP-1 ra to clinical practice.

Speaker: Professor D. Grobbee (Utrecht, NL)
Thumbnail

The cardiovascular challenge for primary care in diabetes.

Speaker: Professor R. Hobbs (Oxford, GB)
Thumbnail

Diabetes: how to reduce risk from a cardiovascular perspective?

Speaker: Professor D. Grobbee (Utrecht, NL)
Thumbnail

Practical management of cardiovascular risk: lessons from latest diabetes trials.

Speaker: Professor L. Ryden (Stockholm, SE)
Thumbnail

Discussion - Preventing cardiovascular disease in patients with T2DM: how to apply novel outcome data with GLP-1 ra to clinical practice.

Speaker: Professor D. Grobbee (Utrecht, NL)
Speaker: Professor R. Hobbs (Oxford, GB)
Speaker: Professor L. Ryden (Stockholm, SE)
Thumbnail

7 speakers from this session

Professor Diederick E Grobbee

University Medical Center Utrecht, Utrecht (Netherlands (The))
33 presentations
0 follower

Professor Richard Hobbs

, Oxford (United Kingdom of Great Britain & Northern Ireland)
8 presentations
0 follower

Professor Diederick E Grobbee

University Medical Center Utrecht, Utrecht (Netherlands (The))
33 presentations
0 follower

Professor Lars Ryden

Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)
32 presentations
0 follower

Professor Diederick E Grobbee

University Medical Center Utrecht, Utrecht (Netherlands (The))
33 presentations
0 follower

Professor Richard Hobbs

, Oxford (United Kingdom of Great Britain & Northern Ireland)
8 presentations
0 follower

Professor Lars Ryden

Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)
32 presentations
0 follower

This platform is supported by

logo Novo Nordisk